Tag: UCB
UCB: Berenberg, for purchase, raises its price target
(CercleFinance.com) – Berenberg reiterated its purchase recommendation on UCB on Thursday, while increasing its price target on the shares of the Belgian pharmaceutical group from 120 to 130 euros. In…
UCB: on the rise, benefits from the positive analysis of a broker
(CercleFinance.com) – UCB gains almost 2% in Brussels, benefiting in particular from an analysis by Deutsche Bank which announced today that it had raised its recommendation on the title of…
Ucb: On the rise, benefits from the positive analysis of a broker
Receive daily value for free every morning The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its service…
UCB: up sharply after raising its target
(CercleFinance.com) – The stock rose by nearly 4% at the end of the day after announcing this morning to expect total income for the year 2022 at the top of…
UCB: set back with analyst comments
(CercleFinance.com) – UCB is down nearly 1% in Brussels, against the backdrop of comments from Oddo BHF which maintains its ‘outperformance’ opinion, but expects ‘another complicated five months before the…
Ucb: Withdrawn with analyst comments
Receive daily value for free every morning The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its service…
Ucb: Positive phase 3 results for bimekizumab
Receive daily value for free every morning The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its service…
UCB: positive phase 3 results for bimekizumab
(CercleFinance.com) – The Belgian pharmaceutical group UCB announced on Friday that bimekizumab had shown its efficacy in two phase 3 clinical studies devoted to the treatment of hidradenitis suppurativa, a…
UCB: the title rises, orphan drug status in the USA
(CercleFinance.com) – The FDA announced on Wednesday that it had granted orphan drug status to fenfluramine hydrochloride, a drug belonging to UCB’s portfolio, for the treatment of epileptic seizures. More…
Ucb: Fall of the title after a setback in the United States
Read also (CercleFinance.com) – The UCB share fell by more than 15% on Friday after the negative opinion of the American drug agency (FDA) on the approval of bimekizumab, its…
UCB: fall in title after a setback in the United States
(CercleFinance.com) – The UCB share fell by more than 15% on Friday after the negative opinion of the American drug agency (FDA) on the approval of bimekizumab, its new treatment…
UCB: targets at least 6 billion euros in turnover in 2025
(CercleFinance.com) – Turnover for the 2021 financial year reached 5.78 billion euros (+8%). Underlying profitability (adjusted EBITDA) stands at 1.64 billion euros (+14%). Profit increased to €1,058 million (+39%) and…